New antibody combo takes aim at Hard-to-Treat lymphoma
NCT ID NCT05737628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested in humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BYON4228 (a lab-made antibody) combined with rituximab (a cancer drug)
What this could lead to
If it works, this could point toward a new treatment option for people with certain types of lymphoma that haven't responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small trial (17 people), so it's mainly checking safety. The drug may not work well or could have side effects, and it's too soon to know if it will help patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Spedali Civili di Brescia
Brescia, Italy
-
Centro Integral Oncológico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
IRCCS Ospedale San Raffaele
Milan, Italy
-
Institut Català d'Oncologia
Barcelona, Spain
-
Instituto Europeo di Oncologia
Milan, Italy
-
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST
Ravenna, Italy
-
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS
Candiolo, Italy
-
Radboud UMC
Nijmegen, Netherlands
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University Hospitals Plymouth NHS Trust
Plymouth, United Kingdom
-
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands